This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Could idebenone by the solution for treating dominant optic atrophy?

Could idebenone by the solution for treating dominant optic atrophy?
Reviewed by Claire Howard

3 September 2024 | Claire Howard | EYE - Neuro-ophthalmology
Share This

Dominant optic atrophy (DOA) is a disease of the retinal ganglion cells, with no current treatment options. In most cases, DOA is caused by a mutation in the OPA1 gene. The aim of this study was to evaluate the effect of idebenone treatment in patients with OPA1 DOA. Sixteen patients with OPA1-DOA were treated with 900mg idebenone daily for one year. The primary endpoint was the best recovery / least deterioration of visual acuity. Secondary endpoints were the changes of visual acuity, colour vision, contrast sensitivity, visual field, peripapillary retinal nerve fibre layer thickness (pRNFLT), and visual-related quality of life. For the primary endpoint, a significant increase was observed for the right eye (p=0.0027), the left eye (p=0.0111) and for the better-seeing eye (p=0.0152). For visual fields, a significant improvement was observed for the left eye between baseline and nine months (p=0.0038). Regarding pRNFLT, a significant decrease was found for the left eye between baseline and three months (p=0.0413) and between baseline and six months (p=0.0448). In the visual function questionnaire, a significant improvement was observed in the subscale general vision (p=0.0156) and in the composite score (p=0.0256). In conclusion, best recovery of visual acuity improved, although the amount of improvement was minimal. Furthermore, a maintenance of visual function after 12 months of idebenone intake could be observed as well as a significant improvement in vision-related quality of life. Further research with a control group is required to determine whether this effect is due to idebenone treatment, the placebo effect, or is explainable by the natural progression of DOA. The authors recommend a randomised, placebo-controlled, and double-blind study over a longer time period to explore further evidence.

Idebenone treatment in patients with OPA1-dominant optic atrophy: a prospective phase 2 trial.
Valentin K, Georgi T, Riedl R, et al.
NEURO-OPHTHALMOLOGY
2023;47(5-6):237–47.
Share This
CONTRIBUTOR
Claire Howard

Salford Royal NHS Foundation Trust, Salford, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency